Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

SUMO2/3 anticorps

L’anticorps Souris Monoclonal anti-SUMO2/3 a été validé pour WB, IF, FACS et IHC (p). Il convient pour détecter SUMO2/3 dans des échantillons de Humain.
N° du produit ABIN3026430

Aperçu rapide pour SUMO2/3 anticorps (ABIN3026430)

Antigène

SUMO2/3 (Small Ubiquitin Related Modifier 2/3 (SUMO2/3))

Reactivité

  • 55
  • 25
  • 24
  • 1
  • 1
  • 1
Humain

Hôte

  • 44
  • 11
  • 1
Souris

Clonalité

  • 29
  • 27
Monoclonal

Conjugué

  • 17
  • 4
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
Cet anticorp SUMO2/3 est non-conjugé

Application

  • 49
  • 26
  • 26
  • 17
  • 14
  • 13
  • 12
  • 12
  • 6
  • 4
  • 1
  • 1
Western Blotting (WB), Immunofluorescence (IF), Flow Cytometry (FACS), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone

SM23-496
  • Attributs du produit

    This antibody reacts with both SUMO2 and SUMO3. The small ubiquitin-related modifier (SUMO) proteins, which include SUMO1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursors that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets for a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO1/2/3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO1 utilizes Ubc9 for conjugation to several targets, which include MDM2, p53, PML and RanGap1. SUMO2/3 contribute to a greater percentage of protein modification than does SUMO1 and they can form polymeric chains. In addition, SUMO3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer's disease.

    Purification

    Protein G purified

    Immunogène

    Recombinant human SUMO2 protein was used as the immunogen for this SUMO2/3 antibody.

    Isotype

    IgG1 kappa
  • Indications d'application

    The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the SUMO2/3 antibody to be titered up or down for optimal performance.

    1. Staining of formalin-fixed tissues requires boiling tissue sections in 10  mM citrate buffer,  pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes.
    2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.\. FACS: 0.5-1 μg/million cells,IF: 0.5-1 μg/mL,WB: 0.5-1 μg/mL,IHC (FFPE): 0.5-1 μg/mL for 30 minutes at RT (1),Prediluted format : incubate for 30 min at RT (2)

    Restrictions

    For Research Use only
  • Concentration

    1 mg/mL

    Buffer

    1 mg/mL in 1X PBS, BSA free, sodium azide free

    Agent conservateur

    Azide free

    Stock

    4 °C,-20 °C

    Stockage commentaire

    Store the SUMO2/3 antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).
  • Antigène

    SUMO2/3 (Small Ubiquitin Related Modifier 2/3 (SUMO2/3))

    Autre désignation

    SUMO2/3

    Sujet

    This antibody reacts with both SUMO2 and SUMO3. The small ubiquitin-related modifier (SUMO) proteins, which include SUMO1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursors that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets for a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO1/2/3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO1 utilizes Ubc9 for conjugation to several targets, which include MDM2, p53, PML and RanGap1. SUMO2/3 contribute to a greater percentage of protein modification than does SUMO1 and they can form polymeric chains. In addition, SUMO3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer's disease.

    ID gène

    6613
Vous êtes ici:
Chat with us!